JIC
SRPT icon

Joel Isaacson & Co’s Sarepta Therapeutics SRPT Stock Holding History

Joel Isaacson & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,500
Closed -$45K – 623
2014
Q2 		$45K Hold
1,500
– – 0.01% 316
2014
Q1 		$36K Hold
1,500
– – 0.01% 339
2013
Q4 		$31K Sell
1,500
-500
-25% -$14.9K 0.01% 328
2013
Q3 		$94K Hold
2,000
– – 0.04% 180
2013
Q2 		$76K Buy
+2,000
New +$71.5K 0.04% 180

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Joel Isaacson & Co's SRPT Position: Q3 2014 in Review

Joel Isaacson & Co sold out of Sarepta Therapeutics (SRPT) in Q3 2014, closing a stake of 1,500 shares — an estimated $45K sold.

Joel Isaacson & Co first reported a position in SRPT in Q2 2013 and held it in 5 quarters. The position peaked at $94K in Q3 2013. 123 funds tracked by Wall St. Rank hold SRPT as of Q3 2014.

  • Joel Isaacson & Co reported no remaining Sarepta Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Joel Isaacson & Co sold 1,500 Sarepta Therapeutics shares in Q3 2014, an estimated $45K.
  • Joel Isaacson & Co first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 5 quarters.
  • Joel Isaacson & Co's Sarepta Therapeutics position peaked at $94K in Q3 2013.
  • 123 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2014.

Based on Joel Isaacson & Co's 13F filing for Q3 2014, filed 22 Oct 2014.